Axitinib, a TKI used to treat advanced renal cell carcinoma with profound HTN as a side effect in over 50% of patients [31], strongly suppressed LEENE and eNOS expression, while inducing VCAM1 expression, both in HUVECs and in mouse aortic rings cultured ex vivo (Figure 5B,C). Here, VCAM1 is linked to hereditary clear cell renal cell carcinoma.